DEC TIMOTHY C — SEC Form 4 filings
SEC reporting owner CIK 1194020. 15 Form 4 filings on record with FilingPulse; latest filed 2026-08-14.
Transaction summary — filings shown
Covers all 15 filings on record, filed 2024-02-26 to 2026-08-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 11,780 shares, $524,092 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 52.
- Largest priced transaction: sale of 11,780 shares @ $44.49 ($524,092) in SUPERNUS PHARMACEUTICALS, INC., filed 2025-08-26.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Senior Vice-President & CFO | 15 | — | 1 leg · 11,780 sh · $524,092 | 52 |
Form 4 filings — DEC TIMOTHY C
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-14 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 1,250 @ $0 · Tax withholding (F): 604 @ $46.57 · Option exercise (M): 1,250 (derivative) @ $0 | EDGAR |
| 2026-07-31 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 1,250 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 3,000 @ $0 · Tax withholding (F): 1,433 @ $54.73 · Option exercise (M): 3,000 @ $0 · Tax withholding (F): 1,450 @ $54.73 · Option exercise (M): 3,000 (derivative) @ $0 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 3,000 (derivative) @ $0 · Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2026-02-26 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 2,500 @ $0 · Tax withholding (F): 1,279 @ $50.69 · Disposition to issuer (D): 2,500 (derivative) @ $0 | EDGAR |
| 2026-02-25 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 1,125 @ $0 · Tax withholding (F): 603 @ $51.35 · Grant/award (A): 500 @ $0 · Tax withholding (F): 242 @ $50.86 · Grant/award (A): 3,000 @ $0 · Tax withholding (F): 1,524 @ $50.86 · +3 more | EDGAR |
| 2026-02-20 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 17,500 (derivative) @ $0 · Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2025-08-26 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Sale (S): 11,780 @ $44.49 | EDGAR |
| 2025-03-11 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 2,000 @ $0 · Tax withholding (F): 1,062 @ $32.06 · Option exercise (M): 1,800 @ $0 · Tax withholding (F): 955 @ $32.06 · Option exercise (M): 2,000 (derivative) @ $0 · Option exercise (M): 1,800 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Tax withholding (F): 276 @ $33.05 · Tax withholding (F): 1,587 @ $33.05 · Tax withholding (F): 1,330 @ $33.05 | EDGAR |
| 2025-03-04 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 2,000 (derivative) @ $0 · Grant/award (A): 1,800 (derivative) @ $0 | EDGAR |
| 2025-02-24 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 500 @ $0 · Grant/award (A): 3,000 @ $0 · Grant/award (A): 2,500 @ $0 · Disposition to issuer (D): 500 (derivative) @ $0 · Disposition to issuer (D): 3,000 (derivative) @ $0 · Disposition to issuer (D): 2,500 (derivative) @ $0 | EDGAR |
| 2025-02-21 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 40,000 (derivative) @ $0 · Grant/award (A): 4,500 (derivative) @ $0 | EDGAR |
| 2024-02-27 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 2,500 @ $0 · Tax withholding (F): 1,314 @ $29.06 · Disposition to issuer (D): 2,500 (derivative) @ $0 | EDGAR |
| 2024-02-26 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 500 @ $0 · Disposition to issuer (D): 500 (derivative) @ $0 · Grant/award (A): 12,000 (derivative) @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1194020 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →